Intracranial hemorrhage during dabigatran treatment

Circ J. 2014;78(6):1335-41. doi: 10.1253/circj.cj-13-1534. Epub 2014 Mar 24.

Abstract

Background: The incidence of intracranial bleeding during dabigatran treatment is lower than that during warfarin treatment. The characteristics of intracranial hemorrhage during dabigatran therapy, however, remain unclear.

Methods and results: The clinical data and treatment summaries of 9 intracranial bleeds that developed during dabigatran treatment in 8 patients with non-valvular atrial fibrillation were retrospectively reviewed. Five patients had small-moderate subdural hematomas, 2 had intracerebral hemorrhage and 1 had traumatic subarachnoid and parenchymal hemorrhage associated with cerebral contusion. Activated partial thromboplastin time upon admission ranged from 31.6 to 72.4s. After admission, systolic blood pressure in the 2 patients with intracerebral hemorrhage was maintained below 140 mmHg, and the subdural hematomas in 4 patients were surgically treated. None of the hematomas became enlarged and outcome was good in most cases.

Conclusions: Hematomas that arise due to acute intracranial bleeding during dabigatran treatment seem to remain small to moderate, hard to expand, and manageable.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antithrombins / administration & dosage
  • Antithrombins / adverse effects*
  • Atrial Fibrillation / blood
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Dabigatran
  • Female
  • Humans
  • Intracranial Hemorrhages / blood
  • Intracranial Hemorrhages / chemically induced*
  • Intracranial Hemorrhages / physiopathology
  • Intracranial Hemorrhages / therapy
  • Male
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*

Substances

  • Antithrombins
  • Benzimidazoles
  • beta-Alanine
  • Dabigatran